SDS Biotech K.K. reported consolidated earnings results for the third quarter ended December 31, 2016. For the year, the company reported net sales of JPY 10,828 million against JPY 10,864 million a year ago. Operating income was JPY 577 million against JPY 560 million a year ago. Ordinary income was JPY 442 million against JPY 380 million a year ago. Net income attributable to owners of parent was JPY 468 million or JPY 59.86 per share against JPY 299 million or JPY 38.23 per diluted share a year ago. Income before income taxes was JPY 441,986 million.

The company revised consolidated earnings guidance for the full year ending March 31, 2017. For the year, the company expects to report net sales of JPY 14,820 million, operating income of JPY 670 million, ordinary income of JPY 610 million, net income of JPY 540 million or JPY 68.95 per share compared to net sales of JPY 16,210 million, operating income of JPY 1,460 million, ordinary income of JPY 1,220 million, net income of JPY 820 million or JPY 104.71 per share as previously expected.

The company also provided dividend guidance for the full year ending March 31, 2017. For the year, the company expects year-end dividend of JPY 12.50 per share compared to JPY 15.00 per share paid dividend a year ago.